EUVIMEDTutustu EUVIMEDiin
Crossref

Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy

D H Lee, M Mendoza, M T Dvorozniak, E Chung, M H van Woert, M D Yahr

Journal of Neural Transmission - Parkinson's Disease and Dementia Section · 1989

DOI: 10.1007/bf02248668 ↗

At a glance

Journal article in Journal of Neural Transmission - Parkinson's Disease and Dementia Section, 1989. Written by D H Lee and 5 co-authors. Institution: Department of Neurology, Mount Sinai School of Medicine, New York City, New York. Cited 21 times so far (Crossref); 18 references. Funded by: NINDS NIH HHS, NCRR NIH HHS.

TiivistelmäSubjectsBibliografiset tiedotCiteRelated studies

Abstract (original language)

Platelet MAO activity was measured in 79 Parkinson patients (56 males and 23 females) before and during L-deprenyl therapy. Baseline platelet MAO activity was higher in females than in males with no age dependent differences. During chronic L-deprenyl therapy, MAO activity was inhibited greater than 98%. Four hours after the oral administration of the first 5 mg dose of L-deprenyl, platelet MAO activity was inhibited by 86%. By 24 hours, greater than 98% inhibition was achieved and this degree of inhibition was maintained during continuous L-deprenyl administration. Following oral administration of 10 mg L-deprenyl once a day versus 5 mg L-deprenyl twice a day, the time course of platelet MAO inhibition was similar. Five days after the termination of chronic L-deprenyl therapy, platelet MAO activity was still inhibited by 96%. MAO activity returned to normal by 2 weeks after stopping L-deprenyl. Platelet MAO activity is a useful method of monitoring bioavailability, compliance, dose-response relationship and optimal dosage schedules for L-deprenyl in Parkinson patients.

Subjects

MeSH terms (MEDLINE)

AdultAgedAged, 80 and overBlood PlateletsDose-Response Relationship, DrugHumansMiddle AgedMonoamine OxidaseParkinson DiseasePhenethylaminesSelegilineSex Factors

Substances

PhenethylaminesSelegilineMonoamine Oxidase

Authors and institutions

  • Department of Neurology, Mount Sinai School of Medicine, New York City, New York.

Funding

  • NINDS NIH HHS
  • NCRR NIH HHS

Cite

APA

Lee, D. H., Mendoza, M., Dvorozniak, M. T., Chung, E., van Woert, M. H., & Yahr, M. D. (1989). Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy. Journal of Neural Transmission - Parkinson's Disease and Dementia Section. https://doi.org/10.1007/bf02248668

Vancouver

Lee DH, Mendoza M, Dvorozniak MT, Chung E, van Woert MH, Yahr MD. Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy. Journal of Neural Transmission - Parkinson's Disease and Dementia Section. 1989. doi:10.1007/bf02248668

BibTeX
@article{Lee1989,
  author = {Lee, D H and Mendoza, M and Dvorozniak, M T and Chung, E and van Woert, M H and Yahr, M D},
  title = {Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy},
  journal = {Journal of Neural Transmission - Parkinson's Disease and Dementia Section},
  year = {1989},
  doi = {10.1007/bf02248668}
}
Start for free →